Research programme: latrepirdine analogues - Medivation

Drug Profile

Research programme: latrepirdine analogues - Medivation

Alternative Names: Research programme: dimebon analogues - Medivation

Latest Information Update: 23 Mar 2012

Price : $50

At a glance

  • Originator Medivation
  • Class Indoles; Small molecules
  • Mechanism of Action Mitochondrial permeability transition pore modulators; Nerve growth factor stimulants; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Huntington's disease

Most Recent Events

  • 17 Jan 2012 Discontinued for Alzheimer's disease in USA (unspecified route)
  • 17 Jan 2012 Discontinued for Huntington's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top